Personalis, Inc. has partnered with Tempus to commercialize NeXT Personal, an ultra-sensitive, whole genome-based liquid biopsy assay for detecting minimal residual disease and cancer recurrence, particularly in breast and lung cancers, and for monitoring immunotherapy across all solid tumors.


  1. Commercial Collaboration: Personalis has joined forces with Tempus to enhance the commercialization of the NeXT Personal liquid biopsy assay.
  2. Precision Detection: The assay detects cancer recurrence with high sensitivity, identifying even a single DNA fragment from cancer amid a million non-cancerous fragments.
  3. Personalized Medicine: NeXT Personal Dx supports oncologists by identifying up to 1,800 unique somatic variants per patient, aiding in personalized treatment decisions.

Personalis, Inc., a provider of advanced genomics for precision oncology, has commenced with commercialization efforts by Tempus for NeXT Personal, Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer. Members of Tempus’ commercial team can now engage in discussions with doctors about the use of the NeXT Personal Dx test for breast and lung cancers and for immunotherapy monitoring across all solid tumors. 

“Today’s announcement opens up new possibilities for cancer patients and we’re excited to be working with Tempus to reach oncologists through our collective efforts,” says Chris Hall, CEO, Personalis. 

Whole Genome-Based Liquid Biopsy Assay Detects Cancer Recurrence Earlier

This announcement follows the launch of NeXT Personal Dx in early access last October. NeXT Personal Dx helps oncologists detect cancer recurrence earlier and aids in treatment decision-making, with the ability to detect in blood just one DNA fragment from cancer in the midst of 1 million non-cancerous DNA fragments.

The ultra-sensitive, personalized MRD whole genome-based liquid biopsy assay identifies up to 1,800 somatic variants unique to each patient’s tumor, supporting physicians in making informed, individualized management decisions for patients.